Core Insights - Elanco Animal Health reported strong financial results for Q4 and full year 2024, achieving its sixth consecutive quarter of organic constant currency revenue growth, with Q4 revenue up 4% [2][4] - The company demonstrated broad-based strength across its diverse portfolio, with growth in both Pet Health and Farm Animal segments, exceeding innovation revenue targets for 2024 and raising the goal for 2025 [2][5] - Elanco generated over $500 million in operating cash flow in 2024, doubling from the previous year, and reported a net loss of $8 million for Q4, significantly improved from a net loss of $141 million in Q4 2023 [4][18] Financial Highlights - Q4 2024 total revenue was $1,020 million, a decrease of 1% on a reported basis but an increase of 4% on an organic constant currency basis compared to Q4 2023 [4][9] - Pet Health revenue for Q4 was $439 million, up 6% year-over-year, driven by strong OTC retail parasiticide sales and key innovation products [10] - Farm Animal revenue for Q4 was $570 million, down 7% on a reported basis but up 2% on an organic constant currency basis, supported by strong demand for specific products [11] Full Year Results - For the full year 2024, Elanco reported total revenue of $4,439 million, flat compared to the prior year on a reported basis and up 3% on an organic constant currency basis [5][7] - Reported net income for 2024 was $338 million, with adjusted net income of $452 million, reflecting significant improvement from a net loss of $1,231 million in 2023 [7][54] - Adjusted EBITDA for 2024 was $910 million, representing 20.5% of revenue, with reported EPS of $0.68 and adjusted EPS of $0.91 [5][7] 2025 Guidance - Elanco provided guidance for 2025, expecting revenue between $4,445 million and $4,510 million, with a reported net loss or income ranging from $(25) million to $7 million [21][22] - The company anticipates a foreign exchange headwind of approximately $110 million to revenue and $45 million to adjusted EBITDA for 2025 [22][24] - For Q1 2025, revenue is expected to be between $1,155 million and $1,180 million, with adjusted EPS projected between $0.29 and $0.34 [25][26] Business Developments - Elanco launched Credelio Quattro™ in January 2025 and achieved significant market penetration with Zenrelia™ in the U.S. [6] - The company strengthened its leadership in the U.S. Farm Animal market, achieving blockbuster status for Experior® [6] - Elanco's strategic investments in innovation and marketing are expected to drive growth in 2025, with a focus on mid-single digit organic constant currency revenue growth [24][22]

Core Insights - Elanco Animal Health has entered into an agreement with Medgene to commercialize a highly pathogenic avian influenza (HPAI) vaccine for dairy cattle, which is in the final stages of review for conditional license approval by the USDA [1][3][4] Industry Context - The poultry industry has faced ongoing challenges in controlling HPAI, which has now affected nearly 1,000 dairy herds across the U.S. since March 2024, highlighting the urgent need for new interventions [2] - The cross-species transmission of HPAI and its zoonotic potential necessitates the development of a cattle vaccine to mitigate the spread of the virus [2] Company Strategy - Elanco's partnership with Medgene aims to provide new solutions to dairy producers, enhancing their vaccination protocols and contributing to the overall health of the dairy industry [3] - The collaboration is expected to strengthen Elanco's diverse dairy portfolio and support its One Health platform, which benefits both dairy and poultry sectors [3] Technological Advancements - Medgene's vaccine platform technology has been previously approved by the USDA, facilitating the accelerated development of the H5N1 vaccine for dairy cattle [4] - Medgene is prepared with existing vaccine manufacturing capabilities to support the U.S. dairy herd [4]

GREENFIELD, Ind., Feb. 21, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that the Company will participate in the following investor conferences.On Thursday, February 27, Todd Young, executive vice president and CFO, will participate in a fireside chat at the Bank of America 2025 Animal Health Summit at 12:30 p.m. ET.On Monday, March 3, Jeff Simmons, president and CEO, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference at 3:10 p.m. ET ...

Core Insights - Elanco Animal Health Incorporated has launched Pet Protect, a line of veterinarian-formulated supplements for dogs and cats, addressing the growing demand in the pet supplement market [1][2][4] - The U.S. pet supplement market reached $2.7 billion in 2023, with a CAGR of 20% over the past five years, indicating strong growth and consumer interest in pet health [2][4] - Pet Protect aims to provide comprehensive support for pets' everyday health, featuring products for joint health, multivitamins, Omega-3, calming, allergy and immune support, and digestive function [4][6] Company Overview - Elanco is a global leader in animal health, dedicated to innovating products and services for the prevention and treatment of diseases in both farm animals and pets [7] - The company has nearly 70 years of experience in animal health and is committed to improving the health of animals while making a positive impact on communities [7] Product Features - Pet Protect is distinguished by its veterinarian-formulated, science-backed supplements, developed with over 25 years of veterinary experience [5][6] - The product line includes specific formulations such as Synovi G3 for joint health, DVM Daily Soft Chews for multivitamin support, and Tranquilify for calming effects [9]

Core Viewpoint - Elanco Animal Health is committed to enhancing veterinary and pet owner education following a warning letter from the U.S. FDA regarding misleading promotional practices related to its product Zenrelia [1][3][5]. Group 1: FDA Warning Letter - The FDA issued a warning letter to Elanco concerning misleading claims in promotional materials for Zenrelia (ilunocitinib tablets), which misbrands the product under the Federal Food, Drug, and Cosmetic Act [3][11][22]. - The letter highlights that the promotional communications create a misleading impression about the safety and effectiveness of Zenrelia, particularly regarding its use in dogs [11][12][22]. - Elanco is required to address the concerns raised in the letter and submit a written response within 15 working days [26][27]. Group 2: Product Information and Safety - Zenrelia is indicated for controlling itching and inflammation associated with skin allergies in dogs over 12 months of age [6][12]. - The FDA-approved prescribing information includes a boxed warning about the risk of fatal vaccine-induced disease and inadequate immune response to vaccines in dogs receiving Zenrelia [8][12][13]. - The promotional materials omitted critical safety information, including specific timeframes for withholding Zenrelia before and after vaccination, which is misleading for pet owners [16][17][18]. Group 3: Company Response and Future Outlook - Elanco is actively reviewing and updating Zenrelia's promotional materials in response to the FDA's concerns and does not expect these adjustments to materially impact Zenrelia's revenue [4][5]. - The company anticipates accelerating organic constant currency revenue growth in the mid-single digits for 2025 [5]. - Elanco emphasizes its dedication to helping veterinarians and pet owners understand the benefits of Zenrelia while ensuring compliance with regulatory standards [2][4].

Core Points - Elanco Animal Health Incorporated will announce its fourth quarter and full year 2024 financial results on February 25, 2025 [1] - A conference call will be held on the same day at 8:00 a.m. eastern time for investors, media, and the public to discuss the company's performance [2] - Elanco is a global leader in animal health, focusing on innovating products and services for the prevention and treatment of diseases in farm animals and pets [3] Company Overview - Elanco has a 70-year heritage in animal health and aims to create value for farmers, pet owners, veterinarians, and society [3] - The company is committed to improving animal health while making a positive impact on local and global communities [3] - Elanco's vision emphasizes the importance of food and companionship in enriching life, supported by its sustainability pillars [3]

Core Insights - Elanco Animal Health has launched Zenrelia, a once-daily oral JAK inhibitor for dogs suffering from allergic dermatitis, which was approved by the FDA in September 2024 [1][2][12] - Approximately 17 million dogs in the U.S. are affected by allergic skin diseases, highlighting a significant market opportunity for effective treatments like Zenrelia [1][2] - A clinical trial involving over 300 allergic dogs demonstrated Zenrelia's effectiveness compared to the leading JAK inhibitor, Apoquel [2][8] Company Overview - Elanco Animal Health is a global leader in animal health, focusing on innovative products and services for disease prevention and treatment in both farm animals and pets [11] - The company emphasizes its commitment to improving animal health and creating value for various stakeholders, including pet owners and veterinarians [11] Product Details - Zenrelia is indicated for controlling itching and inflammation associated with skin allergies in dogs over 12 months of age [12] - The product is designed to start working from the first dose, providing quick relief for dogs suffering from allergic itch [2][4] Market Impact - A survey indicated that 82% of pet owners with itchy dogs are eager for effective treatment solutions, suggesting a strong demand for products like Zenrelia [4] - Real-world results from pet owners show significant improvements in their dogs' conditions after using Zenrelia, reinforcing its market potential [4][9] Clinical Evidence - A newly published study in Veterinary Dermatology compared the clinical outcomes of Zenrelia and Apoquel, providing scientific backing for Zenrelia's efficacy [2][8] - Veterinarians have reported positive outcomes in their patients after using Zenrelia, indicating its acceptance in the veterinary community [10]

Six-in-One Parasite Protection in One Chewable Tablet Six of Six Potential Blockbusters from Elanco Now In-Market GREENFIELD, Ind., Jan. 23, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is now available for veterinarians to order at CredelioQuattroVet.com. With four established and powerful ingredients, Credelio Quattro is designed to deliver the broadest i parasite protection of it ...

I have been investing in common stocks for over 50 years. With all the opportunities and information that is available today, it is more exciting than ever. However, due to extreme current valuations of many stocks, it is increasingly a stock pickers game to find names that have not yet been recognized in the market. The foregoing entails a great deal of work and greater risk, but also the potential for outsized returns. The goal of my writing is to find and research relatively unknown companies that have b ...

GREENFIELD, Ind., Dec. 19, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. Jeff Simmons, president and CEO, will represent the company and respond to questions from analysts at 3:00 p.m. PST (6:00 PM EST). A live audio webcast will be available in the "Events and Presentations" section of Elanco's investor website. A replay will be available for approximately 30 days. ABOUT ELANCOElanco An ...